News and information on generic drugs sold in retail pharmacies, as well as their suppliers.
Sol-Gel and Perrigo's collaboration on generics now covers 10 products.
Approximately 99.6% of votes cast by Mylan shareholders were voted in favor of the proposed combination of Mylan and Upjohn.
Mexiletine hydrochloride has a market value of roughly $16 million, according to IQVIA.
Zydus Cadila’s generic Antivert tablets provide treatment for symptoms associated with motion sickness and vertigo.
Propafenone hydrochloride extended-release capsules had a market value of roughly $51 million for the 12 months ended May 2020, according to IQVIA.
Foram Vaishnav, who leads North American pharmacovigilance and safety for Dr. Reddy's, talked to DSN about what it takes to keep the pharma supply chain safe.
Rivaroxaban tablets — 10 mg, 15 mg and 20 mg — had a market value of $6.1 billion for the 12 months ended March 2020, according to IQVIA.
Bausch + Lomb will be responsible for sales, marketing, and other commercialization efforts for biosimilar Lucentis, following regulatory approval in the United States and Canada.
The ethacrynic acid tablet had a market value of roughly $17 million for the 12 months ended April 2020, according to IQVIA.
Fresenius Kabi’s Simplist MicroVault packaging supports diversion deterrence and secure dispensing of controlled substances.
The Zytiga brand and generic had a market value of approximately $454 million for the most recent 12 months ended March 2020, according to IQVIA.
The FDA has revoked its emergency use authorization for the drugs to treat COVID-19 based on results from a large clinical trial that showed no benefit for decreasing death or speeding recovery.
Dr. Reddy's is acquiring Wockhardt's branded generics, which include respiratory, neurology, VMS, dermatology, gastroenterology, pain and vaccines.
Novartis is launching generic Afinitor tablets in dosage strengths of 2.5 mg, 5 mg and 7.5 mg.